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We describe the preparation of pancreatic enzymes hydrolysate of milk
whey proteins containing low levels of aromatic amino acids. Pancreatin
and trypsin/chymotrypsin (6.3% w/w protein) when used to hydrolyze
whey proteins for 27 h at 37±2 ºC, released 74% of the Phe, 100% of
the Tyr and 100% of the Trp as free amino acids. Most of the free
aromatic amino acids present in 2 kg hydrolysate were separated from
the remaining peptides and other amino acids by gel filtration on a 15
liter Sephadex G-25 column eluted with 5% acetic acid at 60 liters h-
1 at 25ºC. The product, recovered in 37% yield, contained 0.70 mmol
Phe, 0.41 mmol Tyr, and <0.01 mmol Trp/100 mmol recovered amino
acids. The hydrolysate had a general  amino acid composition similar
to the whey proteins from which it was prepared and could be used as
a nitrogen source for patients with phenylketonuria or tyrosinemia
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The hyperphenylalaninemias are a subclass of a
genetic disease complex referred to inborn errors of
metabolism. Phenylketonuria (PKU) is the most common
hyperphenylalaninemia. It is characterized by high levels
of phenylalanine (Phe) in the blood and massive excretion
of its metabolites, due to a deficiency of hepatic
phenylalanine hydroxylase which converts Phe to tyrosine.
Classical PKU untreated children require costly financial
and social institutionalization due to irreversible neurological
damage (Cleary et al., 1994) manifested clinically as
mental retardation (Scriver, Kaufman, Woo, 1989).
The available and effective treatment for classical
PKU is the dietary restriction of Phe (Freitas et al., 1999;
Bowersox, 2001). The efficacy of classical PKU therapy
with low-Phe diet, when used early in infancy has been
amply documented (Grever et al., 1994; Blau & Scriver,
2004). However, diets should contain small and controlled
amounts of Phe to maintain the normal development of
children with PKU (Smith, 1994) since Phe is necessary
for the synthesis of protein and neurotransmitters.
Commercial products available for the treatment of
PKU can be classified into two categories of protein
substitutes: oligomeric diets, composed of protein
hydrolysates, Phe-free or with reduced content, and
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monomeric diets, composed of a balanced mixture of free
synthetic amino acids, completely lacking Phe (Scriver et
al., 1989; Rohr, Munier, Levy, 2001).
Casein and whey proteins are the most important
sources used in the development of protein hydrolysates
for patient nutrition due to an adequate amino acid
composition, large scale commercial availability and
moderate cost (Clemente, 2000). However, since they are
proteins rich in Phe (2.4–9.0% by weight)(Elsas & Costa,
1994), post-hydrolysis procedures are necessary to
eliminate aromatic amino acids before using as a nitrogen
source in diets for PKU patients. There are only a few
descriptions of low Phe protein hydrolysates in the
literature (Nakhost et al., 1982; Arai et al., 1986; Vas-
concelos et al., 1989; Lopez-Bajonero et al., 1992) and
none on a pilot plant or industrial scale.
In the present work, we describe a process for the
preparation of an enzymatic hydrolysate of bovine whey
proteins with low Phe levels, appropriate for use as a nitrogen
source in diets for PKU patients. The characterization of the
protein hydrolysate, in terms of amino acid composition, will
also be described and discussed in relation to its possible use
in the formulation of specialized low-Phe medical foods for the
treatment of PKU patients.
MATERIAL AND METHODS
Material
Bovine milk whey proteins were obtained from a
commercial source in New Zealand and contained 80.9%
protein. Its major protein components were D-lactalbumin
and E-lactoglobulin. The porcine pancreatic proteolytic
enzymes (pancreatic extract containing trypsin, chymo-
trypsin, carboxypeptidases A and B, lypases and amylases,
100 USP units of protease activity mg-1), Proteomix®, a
mixture of bovine and porcine trypsin (2000 USP units mg-
1) and a mixture of bovine and porcine chymotrypsin (400
USP units mg-1), were products from Biobrás S.A. (Mon-
tes Claros, MG, Brazil). Sephadex G-25F for the analytical
column and G-25C for the preparative column were
purchased from Pharmacia (Uppsala, Sweden). Reagents
for amino acid analyses, the Standard H amino acid
mixture, and individual amino acids were obtained from
Pierce Chemical Co. (Rockford, IL, USA). All other
chemicals were of reagent grade or equivalent.
Preparation of whey protein hydrolysates
The conditions for the preparation of three analytical
scale hydrolysates which differ in enzyme content and
digestion time, and one pilot scale hydrolysate are reported
in Table I. For the analytical scale procedure whey protein
dispersed in water (10%, w/v) was hydrolyzed using a pH-
stat in a volume of 250 mL at 37-40 ºC, the pH being kept
at 7.5-8.0 by additions of ammonium hydroxide. The
reaction was stopped by heating to the boiling point for 30
min. After cooling the hydrolysate was clarified by filtration
and lyophilized. Enzyme quantities were reported as
percent (w/w) relative to whey protein in parentheses,
followed by incubation time are as follows: Hydrolysate
A1: pancreatin (1.8%, w/w) and Proteomix® (0.3%, w/w);
the total amount of enzyme was added at time 0h and
incubated for 9h. Hydrolysate A2: pancreatin (3.6%, w/w)
TABLE I - Conditions and recovery data  in the preparation of analytical and pilot plant level whey protein enzymatic
hydrolysates .
Analytical scale, g Pilot scale, kg
A1 A2 A3 P
Total protein 25 g 25 g 25 g 100 kg
Protein (g/v), % 10 10 10 10
Pancreatin, g/100 g 1.8 (1) 3.6 (2) 5.4 (3) 5.4 (3)
Proteomix®, g/100 g 0.3 (1) 0.6 (2) 0.9 (3) 0.9 (3)
Time, h 9 18 27 (3) 27 (3)
Volume, l 0.250 0.250 0.250 1000
Weight recoverya 32 85 87 80
Amino acid recoverya - 81 95 90
Product protein content, % - 76 96 85
Product free Phe content, %b - 59 74 70
aRecovery of soluble material and recovery of amino acids after enzymatic hydrolysis, clarification and lyophilization or spray-
drying . bFree Phe (%) = moles free Phe u 100 /total moles Phe total u 100. - = not determined, due to low recovery.
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and Proteomix® (0.6%, w/w); each half of the total amount
of enzyme was added at 0 and 9 h, respectively; the total
time of incubation was 18h. Hydrolysate A3: pancreatin
(5.4%, w/w) and Proteomix® (0.9%, w/w); each one-third
of the total amount of enzyme was added at 0, 9 and 18h,
respectively; the total time of incubation was 27 h. There
are 3 fold differences in the amount of enzymes and
incubation time when A1 is compared to A3, with A2
occupying an intermediate position in terms of the intensity
of hydrolytic conditions. In pilot scale hydrolysis, conducted
in a 1000 L reactor, we utilized the same conditions of the
hydrolysate A3; pH was monitored and corrected each
two hours. The final dispersion was spray-dried.
Amino acid analyses
Qualitative and quantitative amino acid composition of
intact protein and hydrolysates was determined after acidic
hydrolysis by cation exchange (PC-6A Amino acid analysis
resin, Pierce Chemical Co., Rockford, Il, USA) chromato-
graphic fractionation, and detection by post-column
derivatization with ninhydrin, as described by Spackman,
Stein, Moore (1958), using an automatic amino acid analyzer
(Alonzo, Hirs, 1968). The analyzer consisted of a short
(0.6×17 cm) and a long column (0.6×42 cm), for the
separation of basic (short column), neutral and acidic amino
acids (long column). Chromatographic fractionation was
developed using sodium citrate buffers with different pHs
and ionic strengths and the eluate was treated with ninhydrin
solution for 10 min in a boiling water. After derivatization, the
products were detected by spectrophotometry; 440 and 570
nm was used for detection of proline and other amino acids,
respectively. The system was standardized to operate in a
sensitivity range of 1-10 nM, using an amino acid standard
solution (Pierce H), containing 5.0 nM of each amino acid.
The identification of amino acids was made by retention time
and the quantification by peak height in relation to a constant
(concentration/peak height of standard).
Total amino acids was determined after hydrolysis of
1-2 mg of samples (intact protein or enzymatic hydrolysates)
for 22 hours at 110 ºC in 0.500 mL of constant boiling 6 N
HCl containing 0.01% phenol in an evacuated sealed tube.
Tryptophan (Trp) was determined after hydrolysis of 3-5 mg
of samples (protein or enzymatic hydrolysate) with 4 N
LiOH (Lucas, Sotello, 1980). No corrections were made for
losses of methionine, cysteine, serine, threonine or tyrosine
(Tyr) during acid hydrolysis. Amino acid hydrolysis and
analysis were made in duplicate, with an acceptable variation
of 8% between each duplicates.
The same method was used to measure free amino
acids in samples not submitted to acidic hydrolysis. Small
peptides were distinguished from free amino acids by peak
width and the ratio of absorbance at 570 to 440 nm in the
elution profiles
Yields and recovery calculations
The yield of the process was determined by the ratio
of weight of product (hydrolysate) recovered after
enzymatic hydrolysis and drying to the initial weight of
intact protein.
The ratio of total amount of amino acids (µmoles/mg)
determined in the enzymatic hydrolysate after drying to the
total amino acids determined in the intact protein (not
submitted to enzymatic hydrolysis) was considered as
amino acid recovery.
Total protein content (in mg) was calculated based
on amino acid analyses, i.e., as the values in sum of the
µmoles of each amino acid was multiplied by the
corresponding molecular weight minus one water molecule.
Total amino acids in mg was calculated by the sum of
weights of each individual mg of amino acid. The ratio
between total mg of amino acids and mg to and mg of
sample submitted to amino acid analysis multiplied by 100
was considered as the protein content in the sample.
Gel filtration
The free aromatic amino acids and other amino acids
and peptides in the hydrolysates were separated after gel
filtration on a Sephadex G-25 column developed at 22 ºC
with 5% acetic acid (v/v), as described by Freitas et al.
(1993). In analytical experiments 100 mg hydrolysate, in
2.5 mL of 5% acetic acid containing 1M NaCl, was applied
to a 0.9×250 cm Sephadex G25F column operated at
1.0 mL min-1 and fractions of 1.6 mL were collected. NaCl
was included in the sample solution to prevent electrostatic
interactions of positively charged peptides or amino acids
with a small amount of carboxyl groups which may have
been present due to the oxidation of the resin and to
produce comparative profiles by fixing the elution volume.
Solutes were detected in the effluent by absorbance
at 280nm (amino acids and peptides containing aromatic
amino acids) and by conductivity at 22 ºC in a 1:50 dilution
of the effluent in distilled water (NaCl). The fractions were
combined into pools based on the elution profile as
described by Freitas et al. (1993) and indicated below the
elution profile give in Figure 1B.
The pilot scale gel filtration of 2 kg of hydrolysate was
carried out in a 25×103 cm Sephadex G-25C column. The
sample was applied in a volume of 15 liters in 5% (v/v)
acetic acid and the column eluted with the same solvent at
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FIGURE 1 - Analytical gel filtration chromatography of a whey protein enzymatic hydrolysate. The Sephadex G-25F
column (0.9 × 250 cm) was eluted at 10 ml/h at 22 ºC with 5% (v/v) acetic acid pH 2.5, and 1.6 ml fractions were collected.
Samples were applied in 3.0 mL aliquots of 5% (v/v) acetic acid. The effluent was monitored by absorbance at 280 nm
(closed circles) and by conductivity measurements (closed squares). Panel A: Elution of the calibration mixture  containing
6 mg of bovine serum albumin, 1.6 µmol tyrosine, 1.5 µmol triptofane, and 1 mmol/ml NaCl. Panel B: elution of a sample
containing 100 mg of hydrolysate A3. Tyr = tyrosine, Trp = Tryptophan.
60 liters h-1. One liter fractions were collected, combined
into pools based on the elution profile, as indicated below
the elution diagram (in Figure 2) and spray-dried.
RESULTS AND DISCUSSION
Release of free Phe from whey proteins
Table I describes the experimental hydrolysis
conditions, i.e. quantity of pancreatic proteolytic enzymes
and incubation times carried out on three analytical scale
procedures, (25g whey protein, A1 to A3) and the use of
the most stringent conditions (A3) on a pilot plant scale (P,
100 kg whey protein). Some characteristics of the soluble
fraction obtained after clarification of the hydrolysate are
also given in Table I. Large amounts of the enzymes tested
(6.3% w/w) were required to obtain the highest recovery
of product by weight and in terms of amino acid content
the highest amount of free Phe release (74%). When some
of the conditions used for hydrolysate A3 were applied to
100 kg whey protein, the product was obtained in 90%
yield, with characteristics similar to those obtained on the
25 g analytical scale and with 70% of its Phe in the free
amino acid form.
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FIGURE 2 - Pilot scale gel filtration chromatography of whey protein enzymatic hydrolysates. The Sephadex G-25F
column (25.2 × 103 cm) was equilibrated and eluted at 60 liters/h-1 at 22 ºC with 5% (v/v) acetic acid pH 2.5, and 1 liter
fractions were collected. The hydrolysate P (2.0 kg) was applied in 15 liters of 5% (v/v) acetic acid. The effluent was
monitored by absorbance at 280 nm (closed circles). The curve represented by closed squares shows the amount of
material recovered (mg) after lyophilization of 10 ml of each fraction. The tracing represented by closed triangles shows
the amount of free Phe (µmol/ml) present in the fractions as determined by amino acid analyses.
The selection of suitable enzymes to produce
hydrolysates with defined physicochemical and
nutritional characteristics is essential (Clemente, 2000).
Arai (1986) used a pepsin-pronase system on whey
proteins and Lopez-Bajonero et al. (1992) used the
protease 2A from Aspergillus oryzae and papain to
hydrolyse casein. Pancreatin supplemented with
chymotrypsin were used in our experiments because
they provide the complementary pairs, endopeptidase/
exopeptidase, chymotrypsin/carboxypeptidase A, which
when acting in series can release free aromatic amino
acids from proteins if proline is not adjacent to the
aromatic amino acid (Ambler, 1967). When casein was
treated under similar conditions only 50% of the Phe was
released (See Hydrolysate C, Freitas et al., 1993) and
when pancreatic tissue was used as the source of
proteolytic enzymes, the release of all free amino acids
was increased by 50% but the release of Phe increased
by only 8%, from 50 to 54% (unpublished data from our
laboratory). The inability to release more Phe as the free
amino acid from bovine casein is due to the presence of
the sequences ProPhePro and ProPhe which account for
29% of the Phe present in casein. In contrast, neither
bovine lactoglobulin nor lactoalbumin contain the
sequences ProPhePro or ProPhe (Dayhoff, 1972).
Removal of free Phe from the hydrolysate and
characterization of the low-Phe hydrolysate
The development of protein hydrolysates for patients
with PKU necessarily includes post-hydrolysis procedures to
remove free Phe. Gel filtration on Sephadex G-25 (Nakhost
et al., 1982; Arai, 1986) or on BioRad G-10 and adsorption to
hydrophobic resins (Vasconcelos et al., 1989) have been used
in analytical experiments to separate aromatic amino acids
from other components present in the enzymatic hydrolysates.
Treatment by activated carbon (Lopez-Bajonero et al., 1992)
or the use of ionic exchange resins have also been described
(Heindorff et al., 1988; Matsuo, Hashimoto, Arai, 1986).
We have used a 0.9×250 cm Sephadex G-25
analytical column as described by Freitas et al. (1993) to
separate free aromatic amino acids from the whey
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hydrolysate. The data in Figure 1A shows that both Tyr and
Trp are eluted after NaCl under these conditions. Phe was
eluted between NaCl and Tyr (data not shown).
The elution diagram obtained for hydrolysate A3 is
shown in Figure 1B indicating the absorbance profile at 280
nm and the conductivity measurements of the effluent.
Most of the recovered peptides and free amino acids
(80%) were eluted before the NaCl and present in pools
1 and 2 (indicated by the bars below the elution diagram).
Data shown in Table II indicate that the general
amino acid composition of hydrolysate A3 did not differ
significantly from that of the whey protein from which it
was prepared (compare column 1 with column 3). We
assume the losses of Tyr and Trp were due to their low
solubility, but cannot explain the differences in the loss of
Arg and over recovery of Val. Gel-filtration removed
100% of the Trp, 89% of the Tyr and 75% of the Phe
present in the hydrolysate. The aromatic amino acids
remaining in the bulk of the hydrolysate were present in
peptides and not free. The product, A3 after gel filtration,
contained 0.73 mol% Phe which corresponds to 9.2 mg
Phe/g total protein.
As expected, high efficiency of the separation of the
aromatic amino acids obtained with the 0.9u250 cm
analytical column could not be obtained with the shorter
25.2u103 cm Sephadex G-25 pilot scale column used for
the gel filtration of 2 kg of whey hydrolysate. The data in
Figure 2 shows that the protein was recovered in fractions
20 to 80 corresponding to the first A280nm peak. The second
A280nm peak contains Tyr and Trp. The elution of free Phe
(indicated by the triangles) peaks at fraction 75 indicates
that at least 50% of the recovered hydrolysate is
essentially Phe-free.
The Phe content of 0.70 mol% corresponds to 9.0 mg
Phe/g total protein. Lofenalac, a product based on low-Phe
enzymatic casein hydrolysate available in the market for
dietary treatment of PKU patients, contains 75mg Phe/
100g product (Clemente, 2000). Thus the low-Phe fraction
described here could be used, with appropriate addition of
free amino acids, in the formulation of low-Phe diets
suitable for the treatment of PKU patients; in this case,
tyrosine and triptophan should be added to the resulting diet
to avoid impairment of its nutritional quality.
The analytical and pilot scale processes described in
the present work produced a 70-74% reduction in Phe levels
compared to the starting material (whey proteins), yielding
TABLE II - Amino acid composition of the protein source (whey protein), the A3 hydrolysate, its fraction obtained by
combining pools 1 and 2 and of the pilot level hydrolysate P and the fraction with low Phe.
Whey Analytical scale experiment Pilot scale experiment
Amino acid protein Hydrolysate Fraction pools Hydrolysate Fraction low
A3 1 + 2 P Phe
1 2 3 4 5
Trp 1.55 1.17 <0.01 1.15 <0.01
Lys 8.48 9.24 11.71 9.11 9.18
His 1.64 1.93 2.17 1.92 2.05
Arg 2.12 0.35 0.42 2.85 1.63
Asp 10.32 9.61 11.36 11.05 12.27
Thr 5.59 5.24 6.14 5.69 6.07
Ser 5.68 5.41 6.45 6.02 6.55
Glu 13.79 12.32 15.46 14.82 17.72
Pro 5.63 5.85 7.08 6.19 7.54
Gly 3.81 4.45 4.98 3.88 4.12
Ala 8.15 8.86 10.13 7.88 8.00
Cys 2.73 1.91 2.99 2.07 2.52
Val 2.47 7.23 7.99 6.32 6.10
Met 2.19 2.27 1.68 1.96 1.77
Ile 4.57 6.02 6.01 4.79 4.43
Leu 12.53 13.81 4.40 11.11 8.95
Tyr 2.79 1.16 0.30 1.55 0.41
Phe 2.95 3.20 0.73 2.72 0.70
The data are reported as moles of amino acids/100 moles of total recovered amino acids
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a high protein (~90%) and a low Phe (~9 mg/g total protein)
product. The general amino acid composition of the fractions
described in our work was similar to that of the protein
source, except for the aromatic amino acids, in both
procedures (analytical and pilot level), demonstrating that the
scale-up of these processes was effective and viable. Our
results indicated also that the selective enzymatic hydrolysis
and not the post-hydrolysis processing is the limiting step in
the process of obtaining protein hydrolysates with low-Phe
level. However, the low-Phe hydrolysate described in our
work could still be used in the composition of medical foods
for treatment of PKU or tirosemia patients.
RESUMO
Preparação e escalonamento de um hidrolisado
enzimático de proteínas do soro de leite bovino
Foi descrita a preparação de um hidrolisado de prote-
ínas do soro de leite bovino com enzimas pancreáticas,
contendo baixos níveis de aminoácidos aromáticos.
Quando utilizadas pancreatina e tripsina/quimo-
tripsina, por 27h a 37±2ºC, foram liberados 74% de
Phe, 100% de Tyr e 100% de Trp como aminoácidos
livres. A maioria dos aminoácidos aromáticos livres,
presentes em dois quilos de hidrolisado (15 litros), foi
separada dos peptídeos e outros aminoácidos remanes-
centes por filtração em coluna de gel de Sephadex G-
25C eluída com ácido acético 5%, fluxo de 60 litros por
hora a 25ºC. O produto, recuperado com 37% de ren-
dimento, continha 0,70 mmol de Phe, 0,41 mmol de Tyr
e <0,01 mmol de Trp/100 mmol de aminoácidos recupe-
rados. A composição em aminoácidos do hidrolisado foi
similar às proteínas do soro com as quais foi prepara-
do. Após adição de aminoácidos aromáticos apropria-
dos, ele pode ser usado como fonte de nitrogênio para
pacientes com fenilcetonuria ou tirosinemia.
Unitermos: Dieta pobre em fenilalanina. Fenilcetonúria.
Tirosinemia. Hidrolisado de proteína de soro de leite.
Hidrolisado de pancreatina. Filtração em gel.
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